ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag policy salary biotech publishing

2022 Top 10 Innovations 
2022 Top 10 Innovations
The Scientist | Dec 12, 2022 | 10+ min read
This year’s crop of winning products features many with a clinical focus and others that represent significant advances in sequencing, single-cell analysis, and more.
Science Salaries: Who Makes What Where
Karen Young Kreeger | Dec 5, 1999 | 6 min read
1998 Salaries Interested in what your colleagues are making at the private liberal arts college across town, at biotech and pharmaceutical firms in your region, or at agencies inside the Beltway? Or are you getting ready to hire a new employee or apply for a position in the life sciences? If so, openly discussing salaries with colleagues or at the beginning stages of a job search can be prickly. So how do you get a handle on how much you're worth? The information is out there in many forms. Pr
Controversy Mounts Over Gene Patenting Policy
Scott Veggeberg | Apr 26, 1992 | 5 min read
Scientists in industry and academia foresee trouble as NIH persists in claiming ownership over partial sequences Date: April 27, 1992 The reviews from the scientific community remain mostly negative over the National Institutes of Health's patent application for a total of 2,722 partial human gene sequences. Academic researchers, who say they are mostly unaffected by the patenting process, nevertheless are appalled; and while some in the commercial sector of the biotech community now believe
Flux and Uncertainty in the CRISPR Patent Landscape
Aggie Mika | Oct 1, 2017 | 10 min read
The battle for the control of the intellectual property surrounding CRISPR-Cas9 is as storied and nuanced as the technology itself.
USPTO Issues Biotech Patent Guidelines
Stephen Hoffert | Jul 5, 1998 | 8 min read
In light of several high-profile court cases on patenting of DNA sequences, the U.S. Patent and Trademark Office (USPTO) in June issued interim guidelines for helping patent examiners determine if the so-called "written description" requirement for patent applications has been met. John J. Doll, director of biotechnology examination at USPTO, says the interim guidelines have become necessary to determine just how court decisions such as University of California Regents v. Eli Lilly and Co. wil
Biotech Faces Evolving Patent System
Douglas Steinberg | Mar 5, 2000 | 8 min read
Like medieval alchemists, modern biologists apply intricate, esoteric protocols to lowly matter, such as bacteria and rodents. Unlike alchemists, biologists successfully transmute these creatures into gold--disease-fighting pharmaceuticals and profits accruing from them. An indispensable ingredient in this dross-to-drug process is patent protection, which preserves monopoly and attracts investment. Unfortunately, the patent system isn't as ideal a catalyst as the chimerical philosopher's stone s
Dangling the Carrot: Stock Options
Arielle Emmett | May 14, 2000 | 8 min read
You can't confuse the dot-com revolution with biotech and its stock options," says Edward Abrahams, executive director of the Pennsylvania Biotech Association. "Biotech has much longer lead times to profitability and it's risky business--rooted in the transformation of the [National Institutes of Health] economy," he says. "Scientists shouldn't be in biotech just for the stock. The motivation has to be discovery and creating something--the process of making a contribution for the betterment of
More Biotech Ph.D.'s Opting To Take Postdocs In Industry
Jean Wallace | Oct 11, 1992 | 10+ min read
Better pay and richer research environments in the business sector lure young science grads away from academic labs Two years ago, when Thomas Malvar was finishing his doctorate in molecular immunology, he came to a major career crossroads. Should he go the traditional route and do his postdoctoral training in a university? Or should he follow a more adventurous path and do his postdoc in industry--a road that some of his professors warned was a professional dead end? Like a small but growin
Genome Investigator Craig Venter Reflects On Turbulent Past And Future Ambitions
Karen Young Kreeger | Jul 23, 1995 | 8 min read
And Future Ambitions Editor's Note: For the past four years, former National Institutes of Health researcher J. Craig Venter has been a major figure in the turbulent debates and scientific discoveries surrounding the study of genes and genomes. Events heated up in 1991, when NIH attempted to patent gene fragments, which were isolated using Venter's expressed sequence tag (EST)/complementary DNA (cDNA) approach for discovering human genes (M.A. Adams et al., Science, 252:1651-6, 1991). NIH's mo
Those We Lost in 2019
Ashley Yeager | Dec 30, 2019 | 6 min read
The scientific community said goodbye to Sydney Brenner, Paul Greengard, Patricia Bath, and a number of other leading researchers this year.

Run a Search

ADVERTISEMENT